PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers
Signal transducer and activator of transcription 5 (STAT5) signaling plays a pathogenic role in both hematologic malignancies and solid tumors. In acute myeloid leukemia (AML), internal tandem duplications of fms-like tyrosine kinase 3 (FLT3-ITD) constitutively activate the FLT3 receptor, producing...
Guardado en:
Autores principales: | , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1a37956d049b40a797eb0d03b6d03d1b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:1a37956d049b40a797eb0d03b6d03d1b |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:1a37956d049b40a797eb0d03b6d03d1b2021-11-22T04:20:16ZPARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers1936-523310.1016/j.tranon.2021.101283https://doaj.org/article/1a37956d049b40a797eb0d03b6d03d1b2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1936523321002746https://doaj.org/toc/1936-5233Signal transducer and activator of transcription 5 (STAT5) signaling plays a pathogenic role in both hematologic malignancies and solid tumors. In acute myeloid leukemia (AML), internal tandem duplications of fms-like tyrosine kinase 3 (FLT3-ITD) constitutively activate the FLT3 receptor, producing aberrant STAT5 signaling, driving cell survival and proliferation. Understanding STAT5 regulation may aid development of new treatment strategies in STAT5-activated cancers including FLT3-ITD AML. Poly ADP-ribose polymerase (PARP1), upregulated in FLT3-ITD AML, is primarily known as a DNA repair factor, but also regulates a diverse range of proteins through PARylation. Analysis of STAT5 protein sequence revealed putative PARylation sites and we demonstrate a novel PARP1 interaction and direct PARylation of STAT5 in FLT3-ITD AML. Moreover, PARP1 depletion and PARylation inhibition decreased STAT5 protein expression and activity via increased degradation, suggesting that PARP1 PARylation of STAT5 at least in part potentiates aberrant signaling by stabilizing STAT5 protein in FLT3-ITD AML. Importantly for translational significance, PARPis are cytotoxic in numerous STAT5-activated cancer cells and are synergistic with tyrosine kinase inhibitors (TKI) in both TKI-sensitive and TKI-resistant FLT3-ITD AML. Therefore, PARPi may have therapeutic benefit in STAT5-activated and therapy-resistant leukemias and solid tumors.Anna J. DellomoRachel AbbottsChristian L. EberlyMariusz KarbowskiMaria R. BaerTami J. KingsburyFeyruz V. RassoolElsevierarticleSTAT5 protein stabilityPost-translational modificationsPARYlationPARP inhibitionTKI-resistant FLT3-ITD AMLNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTranslational Oncology, Vol 15, Iss 1, Pp 101283- (2022) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
STAT5 protein stability Post-translational modifications PARYlation PARP inhibition TKI-resistant FLT3-ITD AML Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
STAT5 protein stability Post-translational modifications PARYlation PARP inhibition TKI-resistant FLT3-ITD AML Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anna J. Dellomo Rachel Abbotts Christian L. Eberly Mariusz Karbowski Maria R. Baer Tami J. Kingsbury Feyruz V. Rassool PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers |
description |
Signal transducer and activator of transcription 5 (STAT5) signaling plays a pathogenic role in both hematologic malignancies and solid tumors. In acute myeloid leukemia (AML), internal tandem duplications of fms-like tyrosine kinase 3 (FLT3-ITD) constitutively activate the FLT3 receptor, producing aberrant STAT5 signaling, driving cell survival and proliferation. Understanding STAT5 regulation may aid development of new treatment strategies in STAT5-activated cancers including FLT3-ITD AML. Poly ADP-ribose polymerase (PARP1), upregulated in FLT3-ITD AML, is primarily known as a DNA repair factor, but also regulates a diverse range of proteins through PARylation. Analysis of STAT5 protein sequence revealed putative PARylation sites and we demonstrate a novel PARP1 interaction and direct PARylation of STAT5 in FLT3-ITD AML. Moreover, PARP1 depletion and PARylation inhibition decreased STAT5 protein expression and activity via increased degradation, suggesting that PARP1 PARylation of STAT5 at least in part potentiates aberrant signaling by stabilizing STAT5 protein in FLT3-ITD AML. Importantly for translational significance, PARPis are cytotoxic in numerous STAT5-activated cancer cells and are synergistic with tyrosine kinase inhibitors (TKI) in both TKI-sensitive and TKI-resistant FLT3-ITD AML. Therefore, PARPi may have therapeutic benefit in STAT5-activated and therapy-resistant leukemias and solid tumors. |
format |
article |
author |
Anna J. Dellomo Rachel Abbotts Christian L. Eberly Mariusz Karbowski Maria R. Baer Tami J. Kingsbury Feyruz V. Rassool |
author_facet |
Anna J. Dellomo Rachel Abbotts Christian L. Eberly Mariusz Karbowski Maria R. Baer Tami J. Kingsbury Feyruz V. Rassool |
author_sort |
Anna J. Dellomo |
title |
PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers |
title_short |
PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers |
title_full |
PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers |
title_fullStr |
PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers |
title_full_unstemmed |
PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers |
title_sort |
parp1 parylates and stabilizes stat5 in flt3-itd acute myeloid leukemia and other stat5-activated cancers |
publisher |
Elsevier |
publishDate |
2022 |
url |
https://doaj.org/article/1a37956d049b40a797eb0d03b6d03d1b |
work_keys_str_mv |
AT annajdellomo parp1parylatesandstabilizesstat5inflt3itdacutemyeloidleukemiaandotherstat5activatedcancers AT rachelabbotts parp1parylatesandstabilizesstat5inflt3itdacutemyeloidleukemiaandotherstat5activatedcancers AT christianleberly parp1parylatesandstabilizesstat5inflt3itdacutemyeloidleukemiaandotherstat5activatedcancers AT mariuszkarbowski parp1parylatesandstabilizesstat5inflt3itdacutemyeloidleukemiaandotherstat5activatedcancers AT mariarbaer parp1parylatesandstabilizesstat5inflt3itdacutemyeloidleukemiaandotherstat5activatedcancers AT tamijkingsbury parp1parylatesandstabilizesstat5inflt3itdacutemyeloidleukemiaandotherstat5activatedcancers AT feyruzvrassool parp1parylatesandstabilizesstat5inflt3itdacutemyeloidleukemiaandotherstat5activatedcancers |
_version_ |
1718418208383303680 |